CINECA IRIS Institutional Research Information System

BORGHETTI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.510
NA - Nord America 1.042
SA - Sud America 272
EU - Europa 208
AF - Africa 29
OC - Oceania 1
Totale 4.062
Salva come PNG Salva come JPEG
Nazione #
CN - Cina 1.343
US - Stati Uniti d'America 1.013
SG - Singapore 541
HK - Hong Kong 312
BR - Brasile 224
VN - Vietnam 120
IT - Italia 60
KR - Corea 57
FI - Finlandia 35
JP - Giappone 31
IN - India 22
DE - Germania 19
GB - Regno Unito 19
BD - Bangladesh 17
AR - Argentina 15
AT - Austria 13
MX - Messico 13
FR - Francia 11
RU - Federazione Russa 11
MA - Marocco 9
CA - Canada 8
CO - Colombia 8
IQ - Iraq 8
NL - Olanda 8
EC - Ecuador 7
PK - Pakistan 7
SA - Arabia Saudita 7
ZA - Sudafrica 7
TR - Turchia 6
CL - Cile 5
ES - Italia 5
PH - Filippine 5
AZ - Azerbaigian 4
ID - Indonesia 4
LT - Lituania 4
PL - Polonia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
KE - Kenya 3
KZ - Kazakistan 3
PY - Paraguay 3
SE - Svezia 3
TH - Thailandia 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
UZ - Uzbekistan 3
BO - Bolivia 2
ET - Etiopia 2
IE - Irlanda 2
LB - Libano 2
OM - Oman 2
PE - Perù 2
AO - Angola 1
AU - Australia 1
BE - Belgio 1
BM - Bermuda 1
BS - Bahamas 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LV - Lettonia 1
MY - Malesia 1
MZ - Mozambico 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TM - Turkmenistan 1
TW - Taiwan 1
UG - Uganda 1
UY - Uruguay 1
Totale 4.062
Salva come PNG Salva come JPEG
Città #
Shanghai 1.113
Hong Kong 311
Singapore 305
San Jose 224
Santa Clara 220
Boardman 100
Hefei 85
Ashburn 64
Seoul 57
Ho Chi Minh City 45
Los Angeles 37
Helsinki 30
Tokyo 30
Hanoi 28
Beijing 22
São Paulo 20
Chicago 19
Dallas 17
Nuremberg 14
Redondo Beach 14
New York 13
Council Bluffs 12
Buffalo 11
Baltimore 10
Rio de Janeiro 9
Lauterbourg 8
Florence 7
Rome 7
Guarulhos 6
Haiphong 6
Mexico City 6
Orem 6
Salt Lake City 6
Belo Horizonte 5
Brasília 5
Wuhan 5
Atlanta 4
Baku 4
Brooklyn 4
Chennai 4
Frankfurt am Main 4
Guangzhou 4
Jeddah 4
Lappeenranta 4
Miami 4
Osasco 4
Pescara 4
Phoenix 4
Pisa 4
Porto Alegre 4
Santiago 4
Secaucus 4
Thái Bình 4
Warsaw 4
Amsterdam 3
Bologna 3
Bắc Ninh 3
Canoas 3
Casablanca 3
Curitiba 3
Dhaka 3
Houston 3
Hyderabad 3
Hải Dương 3
La Paz 3
London 3
Lucca 3
Manchester 3
Misterbianco 3
Montreal 3
Nairobi 3
Quito 3
Ribeirão Preto 3
Riverside 3
Stockholm 3
Tampa 3
Tashkent 3
Vienna 3
Addis Ababa 2
Ankara 2
Asunción 2
Baghdad 2
Barranquilla 2
Betim 2
Blumenau 2
Cao Lanh 2
Cape Town 2
Capão da Canoa 2
Cardiff 2
Castellanza 2
Caxias do Sul 2
Chandigarh 2
Changsha 2
Denver 2
Dubai 2
Faisalabad 2
Genoa 2
Guayaquil 2
Indianapolis 2
Inverness 2
Totale 3.065
Salva come PNG Salva come JPEG
Nome #
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 484
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 265
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 169
SARS-CoV-2 infection in a highly experienced person living with HIV 101
Integrase inhibitors use and cmv infection predict immune recovery in people living with hiv starting first-line therapy 86
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 79
No significant changes in body fat mass in virologically suppressed, HIV- positive patients switched to lamivudine-dolutegravir 77
Cardiovascular disease risk in a cohort of virologically-suppressed PLWHIV switching to doravirine: preliminary data from the real life 68
Shall We Dance? Extending TANGO's Results to Clinical Practice 66
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 66
Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice 65
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 65
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak 58
Autochthonous dengue outbreak in Rome, Italy, in 2023 56
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 54
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 48
Experienced PLWH switching to DOR/3TC/TDF in outpatient setting: real-word data on tolerability and Cost Savings from an Italian multicenter cohort 47
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 47
Investigating seroprevalence of IgG antibodies against Monkeypox Virus (MPXV) in a cohort of people living with HIV (PLWH) in Rome, during the 2022 outbreak: Moving beyond traditional at-risk populations 46
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis 46
Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report 46
Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores 46
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 45
Cohort profile: the observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 44
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 43
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 43
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 42
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 41
How do I manage disseminated Mycobacterium avium complex disease in people with HIV? 40
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 40
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 39
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine 39
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 39
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 38
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort 37
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 37
Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy 34
Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer breast receiving neoadjuvant chemotherapy 32
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 28
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 26
Focal status epilepticus as unique clinical feature of COVID-19: A case report 26
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 26
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 24
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 24
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 24
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 23
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice 22
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. 22
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 22
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 22
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey 22
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 22
Liver fibrosis is associated with cognitive impairment in people living with HIV 22
People Living with HIV in the COVID-19 Era: A Case Report. 22
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice 21
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 21
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 21
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 21
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 21
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 20
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 20
Kaposi-like manifestations in a newly diagnosed AIDS transgendered patient with silicone embolism syndrome and disseminated tuberculosis 20
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 20
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 20
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 19
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 19
Atlas-M Study Group. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 19
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey 19
Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy 19
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 19
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study 19
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 19
COVID-19 diagnosis does not rule out other concomitant diseases 19
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 19
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. 18
Infections in hospitalised patients affected by end-stage diseases: a narrative overview 18
Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort StudyImpact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based 18
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 17
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 17
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 17
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 17
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV. 17
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 16
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice 16
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 16
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 16
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 16
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 16
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 15
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 15
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 15
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 15
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015 15
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 15
ATLAS-M Study Group . Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 15
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 15
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 15
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 15
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 14
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 14
Totale 3.903
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.505
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.505
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024132 0 0 0 0 0 99 0 6 1 3 0 23
2024/20252.512 2 99 123 4 114 170 1.141 77 68 172 167 375
2025/20261.575 62 267 150 155 156 72 259 127 128 141 58 0
Totale 4.219